World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Three Days Of Hearings Yield Five Take-Aways
Keywords:
A sense of how the U.S. Supreme Court Justices viewed key aspects of the Obama Health Care Law after three days of hearings on March 28, 2012.
The parts of the Obama U.S. Health Care Law that are likely to be retained and the parts that may be ignored if the Supreme Court overturns it in 2012
03/22/2012
Grouped Articles
Washington Post 03/23/2012
Obamacare: The reckoning - The Washington Post
Washington Post 03/23/2012
New York Times 03/22/2012
Wall Street Journal 03/23/2012
Washington Post 03/25/2012
Washington Post 03/26/2012
The U.S. Supreme Court and the Affordable Care Act (Obama U.S. health care law)
11/03/2011
Grouped Articles
Health Care Is Defining Decision for Chief Justice Roberts
New York Times 06/28/2012
Chief Justice John Roberts’s health-care ruling gets plenty of second-guessing - The Washington Post
Washington Post 06/30/2012
New York Times 06/30/2012
What the Supreme Court Challenge Means for the Health-Care Law
Wall Street Journal 03/03/2015
Justices Divided at Health-Law Argument
Wall Street Journal 03/05/2015
Some Supreme Court Justices Cite 2012 Argument Against Health Care Law as Defense for It Now
New York Times 03/08/2015
India's Supreme Court and Novatis leukemia drug Gleevec
03/06/2012
The issues of what drugs are patentable in India,"evergreening" for patents, and public health concerns throughout developing countries, that are now before the Indian Supreme Court. India permitted the patenting of drugs only since 2005 under a WTO agreement, and there are restrictions on "evergreening," or small modifications of existing drugs for marketing. Novartis and other pharmaceutical companies aim to use the case to restrict Indian generic pharmaceuticals manufacturers from coming up with lowcost versions of new drugs. The leukemia treatment developed by Novartis costs over $70,000, by comparison Indian generic manufacturers can make a version of this for $2500.
Grouped Articles
India Orders Bayer to License Patented Cancer Drug
New York Times 03/12/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Three Days Of Hearings Yield Five Take-Aways
Wall Street Journal 03/29/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us